Asthma/COPD is a common respiratory disease in my country, with more than 53 million asthma patients. The prevalence rate in adults is 4.2%, and the prevalence rate in children is 3.07%, with about 7.6 million children. According to statistics, about 30% of urban children with asthma are not diagnosed in time, and more than 20% of children with asthma are not well controlled. There is a huge unmet clinical demand. According to the guideline data, the prevalence of COPD in adults aged 20 and above in my country is 8.6%, and that in adults aged 40 and above is as high as 13.7%. It is estimated that the number of COPD patients in my country is nearly 100 million.

According to the full-terminal data of the hospital market of Yaorongyun, although the asthma/COPD drug market has fluctuated due to external factors such as the epidemic and centralized procurement, it has continued to grow overall, with a compound growth rate of 11.7% under a market size of more than 20 billion yuan. After the centralized procurement of multiple blockbuster products, the year-on-year growth in 2023 will still be as high as 24%. It can be seen that the huge market size and clinical demand for long-term medication in the field of asthma/COPD have brought a surging market vitality to the medication field.

In the asthma/COPD clinical drug market, the TOP1 category is inhaled glucocorticoids (ICS), with sales of 5.2 billion yuan in 23 years, accounting for as much as 21%; among them, the sales of inhaled budesonide suspension remain the best, but it has entered the national centralized procurement in 2021, and the sales price has dropped significantly. Fluticasone entered the Chinese market in 2018, and its product sales have grown rapidly, and it has become a dark horse in this field.

Asthma guidelines at home and abroad, such as the Global Initiative for Asthma (GINA), Guidelines for the Prevention and Treatment of Bronchial Asthma (2020 Edition), and Guidelines for the Diagnosis and Prevention of Bronchial Asthma in Children (2016), all recommend ICS as a classic anti-inflammatory drug for asthma. ICS has a strong local anti-inflammatory effect, the drug acts directly on the respiratory tract, the required dose is small, and there are fewer systemic adverse reactions. It can also effectively control airway inflammation, reduce airway hyperresponsiveness, relieve asthma symptoms, improve lung function, improve quality of life, reduce the frequency of asthma attacks and reduce the severity of attacks, and reduce mortality.

Chenbang Pharmaceutical's Chenkeshu® Fluticasone Propionate Nebulized Inhalation Suspension is the latest ICS in China to pass the national consistency evaluation. It not only has the excellent anti-inflammatory characteristics of ICS, but also has unique competitive advantages. Chenkeshu® is an ICS of the same dosage form and category as budesonide. In 2023, the national hospital terminal sales of budesonide suspension for inhalation will exceed 4 billion yuan, and the annual sales will exceed 1 billion units. Although it has entered the centralized procurement, its sales and volume have both shown a surge trend, and clinical needs have not yet been met, and various manufacturers have different degrees of supply shortages.

Glucocorticoids have a wide range of anti-inflammatory effects, and are known to have an inhibitory effect on the production of chemical mediators and cytokines related to inflammation. It has been confirmed that respiratory inflammation is the main cause of bronchial asthma. The reason why glucocorticoids can effectively treat asthma is that glucocorticoids have significant anti-inflammatory effects.

Chenkeshu® Fluticasone Propionate is a specific agonist of glucocorticoid receptors, so it can exert a strong anti-inflammatory effect when administered locally in the respiratory tract. Therefore, the magnitude of the anti-inflammatory effect is directly related to the control of asthma. Compared with budesonide nebulized inhalation suspension, it has a stronger anti-inflammatory effect and can better control the acute onset of asthma and the effective control of the remission period.

Chenkeshu® Fluticasone Propionate Suspension for Nebulized Inhalation has low oral bioavailability in the liver, high first-pass metabolism rate in the liver, and very small amount entering the systemic blood circulation, which can effectively avoid systemic adverse reactions of glucocorticoids such as osteoporosis, growth retardation, cardiovascular disease, and digestive system diseases.
In particular, various clinical studies have shown that fluticasone can achieve the same or even better asthma control or lung function improvement as budesonide at half the dose due to its stronger anti-inflammatory activity. This is especially meaningful for infants and children, the main applicable population for nebulized suspensions, and can well solve the concerns of patients' families about the growth retardation and height of their children.

Chenkeshu® Fluticasone Propionate Suspension for Nebulized Inhalation is a heavyweight inhalation product of Shanghai New Yellow River Pharmaceutical Co., Ltd., a subsidiary of Shanghai Chenbang Pharmaceutical Group and a Shanghai high-tech enterprise. The company attaches great importance to product life cycle management, has a rich marketing team, fully cooperates with the establishment and maintenance of national and regional experts, and deeply supports the product's entry into hospitals and product volume work. The company adheres to the corporate mission of "striving for excellent drugs to benefit more patients" and aims to become the leader of dry powder inhalation preparations in China. The company's subsequent pulmonary drug delivery products are under development, and there are plans to launch dual- and triple-inhalation closed preparations. In the current pharmaceutical market environment, we can work together with Chenbang Pharmaceutical to jointly contribute to the field of pulmonary drug delivery in the future.

https://mp.weixin.qq.com/